HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Private label ranitidine

This article was originally published in The Tan Sheet

Executive Summary

The H2 antagonist has begun reaching shelves at drug chains and wholesalers, mass merchandisers, food chains and warehouse clubs nationwide, Toronto, Canada-based Novopharm says. The product began shipping July 19. Novopharm says its subsidiary, Granutec, has shipped over 170 mil. tablets "to meet anticipated consumer demand for the lower cost generic." Warner-Lambert lost marketing exclusivity for the reference drug, Zantac 75, June 19. FDA granted Novopharm 180 days of marketing exclusivity for the private label version that is set to expire Jan. 19; the decision was challenged by Apotex but upheld by a D.C. federal court June 15 (1"The Tan Sheet" June 21, p. 3)

You may also be interested in...



W-L Listerine, Halls Post Strong Sales Growth In 1999

Warner-Lambert's Listerine mouthwash recorded sales of $487 mil. in 1999, a 13% gain over the prior year, the company announced Jan. 19. The brand's healthy performance reflects the marketing and development commitment shown by W-L throughout the year.

Ranitidine OTC Private Labels Ready For January Launch

At least three private label marketers will launch OTC 75 mg ranitidine immediately upon termination of Novopharm's 180-day marketing exclusivity Jan. 19. Perrigo, PL Developments and Zenith Goldline Pharmaceuticals showcased their versions of the H2 antagonist at the Private Label Manufacturers Association annual trade show in Chicago Nov. 14-16.

Novopharm Entitled To OTC Ranitidine Generic Exclusivity - Federal Judge

Novopharm is entitled to 180 days of generic marketing exclusivity for OTC ranitidine 75 mg, D.C. federal court Judge Emmet Sullivan rules June 15 in Apotex vs. Shalala. In his opinion, Sullivan upholds FDA's interpretation of the generic exclusivity provisions of the Waxman/Hatch Act.

Related Content

Topics

UsernamePublicRestriction

Register

RS140877

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel